Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07290283 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants
A Phase 1 study of Healthy Participants, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 176
- Enrollment target
- 2
- Study locations
NCT07290283: Recruiting Phase 1 study of Healthy Participants, sponsored by AstraZeneca.
NCT07290283 is a Phase 1 study of Healthy Participants that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 176 participants, above the 64-participant average among 119 other Healthy Participants trials with a reported enrollment target (175% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07290283, a Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 176 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of AZD3974 and characterize the pharmacokinetics (PK) of AZD3974 following oral administration to healthy participants, including participants of Japanese and Chinese descent.
Primary Outcome
To assess the safety and tolerability of AZD3974 following oral administration of single and multiple ascending doses in healthy participants, including Chinese and Japanese participants
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AZD3974
Study Locations (2)
California
- Research Site - Glendale
Maryland
- Research Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2025-12-10 |
| Est. Completion | 2026-10-21 |
| Phase | Phase 1 |
What NCT07290283 shows while recruiting
NCT07290283 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, above the 64-participant average among 119 other Healthy Participants trials with a reported enrollment target (175% higher).
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07290283 reports a single indexed study location in California, Maryland.
Frequently Asked Questions
What is clinical trial NCT07290283 about?
NCT07290283 is a clinical study titled "A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants". The purpose of this study is to assess the safety and tolerability of AZD3974 and characterize the pharmacokinetics (PK) of AZD3974 following oral administration to healthy participants, including participants of Japanese and Chinese descent.
What is the current status of trial NCT07290283?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 176 participants. The study started on 2025-12-10. Estimated completion is 2026-10-21.
What conditions does trial NCT07290283 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT07290283?
The interventions under investigation include: Placebo (OTHER), AZD3974 (DRUG).
Who is sponsoring clinical trial NCT07290283?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07290283 being conducted?
This trial has 2 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07290283's enrollment target sits among peer trials
176 8th of 119 higher than 112 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT03824145 · 176 participants · NA
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI